GoAI
Get started
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals

2561.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$19.98

HK$0.00 · 0.00%

Aug 24, 9:42 AM HKTData delayed

2561.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
An-bang Lu
Listed since
Mar 21, 2025
Employees
82

Market position

52-week range

Current HK$19.98

Open
HK$19.98
Previous close
HK$19.98
Volume
300
0.01× average
Average volume
31.49K
Average daily volume
Market cap
2.18B HKD
Beta
0.94
Market reference 1
50-day average
HK$20.0614
-0.41% below average
200-day average
HK$27.7128
-27.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.6B CNY
P/E (TTM)
-7.02×
P/B (TTM)
2.41×
P/S (TTM)
-743.4×
EV / EBITDA
-10.43×
Earnings yield
-8.08%
Free cash flow yield
-14.74%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
105.81%
Operating margin
9652.43%
Net margin
10088.46%
Return on equity
-32.38%
Return on assets
-25.25%
Return on invested capital
-24.87%

Financial health

Debt / equity
0.23×
Current ratio
4.47×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends32509%-35163%-102835%-170508%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 11.51%Operating margin, FY2022: 15591.21%Operating margin, FY2023: 8318.15%Operating margin, FY2024: -6272.16%Operating margin, FY2025: -145329.04%Net margin, FY2022: 12574.72%Net margin, FY2023: 14953.27%Net margin, FY2024: -6562.55%Net margin, FY2025: -153589.68%FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 11.51%. Operating margin FY2022 15591.21%. Operating margin FY2023 8318.15%. Operating margin FY2024 -6272.16%. Operating margin FY2025 -145329.04%. Net margin FY2022 12574.72%. Net margin FY2023 14953.27%. Net margin FY2024 -6562.55%. Net margin FY2025 -153589.68%.

Income trends

Revenue

160.73K CNY-94.21%

Operating income

−233.59M CNY-34.11%

Net income

−246.86M CNY-35.46%
Income trends across reported periods38.88M CNY−105.54M CNY−249.97M CNY−394.39M CNYRevenue, FY2022: −2.3M CNYRevenue, FY2023: −1.67M CNYRevenue, FY2024: 2.78M CNYRevenue, FY2025: 160.73K CNYOperating income, FY2022: −358.29M CNYOperating income, FY2023: −138.83M CNYOperating income, FY2024: −174.18M CNYOperating income, FY2025: −233.59M CNYNet income, FY2022: −288.97M CNYNet income, FY2023: −249.57M CNYNet income, FY2024: −182.24M CNYNet income, FY2025: −246.86M CNYFY2022FY2023FY2024FY2025
Revenue FY2022 −2.3M CNY. Revenue FY2023 −1.67M CNY. Revenue FY2024 2.78M CNY. Revenue FY2025 160.73K CNY. Operating income FY2022 −358.29M CNY. Operating income FY2023 −138.83M CNY. Operating income FY2024 −174.18M CNY. Operating income FY2025 −233.59M CNY. Net income FY2022 −288.97M CNY. Net income FY2023 −249.57M CNY. Net income FY2024 −182.24M CNY. Net income FY2025 −246.86M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022
Revenue160.73K CNY2.78M CNY−1.67M CNY−2.3M CNY
Cost of goods sold142.22K CNY———
Gross profit18.51K CNY2.78M CNY−1.67M CNY−2.3M CNY
Research and development91.06M CNY90.52M CNY57.69M CNY179.55M CNY
Selling, general, and administrative146.33M CNY86.43M CNY16.35M CNY41.51M CNY
Operating expenses233.6M CNY174.18M CNY138.83M CNY358.29M CNY
Interest income11.47M CNY6.77M CNY11.15M CNY5.57M CNY
Interest expense1.07M CNY161K CNY317K CNY619K CNY
Depreciation and amortization3.17M CNY4.47M CNY7M CNY7.4M CNY
Operating income−233.59M CNY−174.18M CNY−138.83M CNY−358.29M CNY
Net income−246.86M CNY−182.24M CNY−249.57M CNY−288.97M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-1.29

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.58-0.83-1.09-1.35Q2 '25Q3 '25
Q2 2025, reported Apr 30, 2025: actual -0.63, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 27, 2025: actual -1.29, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates-901.06K-934.67K-968.28K-1MQ2 '25Q3 '25
Q2 2025, reported Apr 30, 2025: actual -939.59K HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 27, 2025: actual -963.36K HKD, estimate —, surprise —, Comparison unavailable.

2561.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

Continue in GoAI

Research 2561.HK

research.disclaimer